Analyst Price Targets — CUE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 15, 2024 1:59 pm | Maury Raycroft | Jefferies | $4.00 | $1.29 | StreetInsider | Cue Biopharma (CUE) PT Lowered to $4 at Jefferies |
| July 26, 2024 6:14 am | Reni Benjamin | JMP Securities | $2.00 | $0.70 | TheFly | Cue Biopharma price target lowered to $2 from $15 at JMP Securities |
| March 13, 2024 2:52 am | Maury Raycroft | Jefferies | $6.00 | $2.15 | StreetInsider | Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy' |
| November 20, 2022 6:23 pm | Edward Tenthoff | Piper Sandler | $7.00 | $3.22 | TheFly | Cue Biopharma initiated with an Overweight at Piper Sandler |
Latest News for CUE
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price…
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative therapies targeting…
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City.
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CUE.
U.S. House Trading
No House trades found for CUE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.